Breast Cancer News and Research

Latest Breast Cancer News and Research

Study identifies causes of bone loss in breast cancer survivors

Osteoporosis is a growing concern among breast cancer survivors and their doctors, because certain cancer drugs can cause bone loss.

19 Nov 2008

Power3 Medical files two patent applications for breast cancer blood test

Power3 Medical Products, Inc. said today that two CIP patent applications have been filed for BC-SeraPro Breast Cancer blood test and biomarkers by Dr. Ira Goldknopf, its president and Chief Scientific Officer.

19 Nov 2008

Amgen, Takeda and Millennium update on phase 3 trial of Motesanib in non-small cell lung cancer

Amgen and Millennium: The Takeda Oncology Company, a subsidiary of Takeda Pharmaceutical Company Limited , today announced that enrollment in the Phase 3 MONET1 trial evaluating motesanib (AMG 706) in combination with paclitaxel and carboplatin for the first-line treatment of advanced non-small cell lung cancer (NSCLC) has been temporarily suspended following a planned safety data review of 600 patients by the study's independent Data Monitoring Committee (DMC). Motesanib is part of a broad co-development program between Amgen and Takeda.

19 Nov 2008

Cancer drug bevacizumab linked to significantly increased risk of blood clots

An analysis of randomized controlled trials indicates that use of the cancer drug bevacizumab is associated with an increased risk of venous thromboembolism (blood clots in the deep veins of the legs or in the lungs), according to an article in the November 19 issue of JAMA, the Journal of the American Medical Association.

18 Nov 2008

Early breast health education may be key to lowering breast cancer mortality rates

Project Early Awareness, a breast cancer education program of Howard University Cancer Center, brings a young survivor into high school classrooms to dispel breast cancer myths, provide breast cancer facts, and teach breast self exams.

18 Nov 2008

ER/PR negative tumors associated with insurance status

African-American women are at a higher risk for ER/PR negative breast cancer.

18 Nov 2008

Dilon Technologies forms alliance with Terason Ultrasound in diagnostic imaging

Dilon Technologies, Inc., the leader in molecular breast imaging, announced today that they have formed an alliance with Terason Ultrasound to offer an expanded imaging capability when molecular breast imaging and ultrasound may be required.

18 Nov 2008

Reduced-calories and exercise can modify a postmenopausal woman's risk of breast cancer

Scientists at the University of Texas at Austin have identified pathways by which a reduced-calorie diet and exercise can modify a postmenopausal woman's risk of breast cancer.

18 Nov 2008

Latina women more likely to regret breast cancer treatment decisions

Latina women who prefer speaking Spanish are more likely than other ethnic groups to express regret or dissatisfaction with their breast cancer treatment, according to a new study by researchers at the University of Michigan Comprehensive Cancer Center.

18 Nov 2008

Celprogen introduces in vivo model for human glioblastoma

Celprogen Inc. has announced that they have successfully validated an in vivo model system for testing efficacy of cancer drugs and also novel drug candidates for Human Glioblastoma.

18 Nov 2008

Palladin may play important role in metastasis of breast cancer cells

If scientists knew exactly what a breast cancer cell needs to spread, then they could stop the most deadly part of the disease: metastasis.

17 Nov 2008

Researchers find deadly protein that acts as a cancer master switch

Two critical properties of cancer cells are their ability to divide without restraint and to spread away from the primary tumor to establish new tumor sites.

17 Nov 2008

Study suggests Siemens non-invasive blood test may have a role in monitoring breast cancer patients' response to Herceptin

Siemens Healthcare announced that data from a new study published in the American Cancer Society journal Cancer, supports using the Siemens Serum HER-2/neu test to monitor patients with an aggressive type of metastatic breast cancer.

17 Nov 2008

Scientists identify dangerous 'two-faced' protein crucial to breast cancer spread and growth

Two critical properties of cancer cells are their ability to divide without restraint and to spread away from the primary tumor to establish new tumor sites.

17 Nov 2008

Breakthrough reveals first ever complete structure of a nuclear hormone receptor on human DNA

For decades, scientists have been studying nuclear hormone receptors to gain a better understanding of how they turn genes on and off throughout the body and how they function as key drug targets for a number of diseases, such as diabetes, breast cancer, osteoporosis and high cholesterol. A new UVA Health System study, led by Fraydoon Rastinejad, Ph.D., professor of pharmacology and director of the UVA Center for Molecular Design and published in the October 29 issue of Nature, reveals the first ever complete structure of a nuclear hormone receptor on human DNA – a discovery that now clears a new path for scientists to design more effective drugs with fewer associated health risks. “Dr. Rastinejad’s findings fundamentally change the way people all over the world will study how nuclear hormone receptors work and introduces a new platform for designing better drugs,” says Jim Garrison, Ph.D., professor of pharmacology at UVA Health System. Nuclear hormone receptors, including the peroxisome proliferator-activated receptors (PPARs), are proteins that sit on the surface of cells and bind to specific hormones such as estrogen, progesterone and thyroid hormone. Once the receptor binds to its hormone and its DNA regulatory element, it can cause a number of alterations in the cell, switching genes on and off. These switches control the continual regulation of the metabolic system and reproductive tissues, as well as the development and differentiation of skin, bone and behavioral centers in the brain. “PPARs are widely studied because they regulate the genes that produce fat cells, glucose, insulin, lipids and metabolism,” says Dr. Rastinejad. “That’s what makes them such good drug targets for diseases like diabetes. We can design drugs more rationally to bind to the PPAR nuclear receptor complex to help regulate these functions in the body.” A number of diabetes drugs, called insulin sensitizers, have been developed based on that knowledge, but now that scientists have a clear view into how these receptors bind and what shape they take the door is wide open for the development of better drugs. "After 40 years of nuclear receptor research, we finally can view the first full and complete structure of a nuclear receptor, thanks to Dr. Rastinejad’s break-though achievement,” says Bert W. O’Malley, Ph.D., professor and chairman, Department of Molecular and Cellular Biology at Baylor College of Medicine who is widely considered a top expert in the field.

17 Nov 2008

Intervention program boosts survival in breast cancer patients

A new study provides the best evidence to date that a psychological intervention program designed for breast cancer patients not only improves their health - it actually increases their chance of survival.

17 Nov 2008

Early detection program for men with a high prostate cancer risk

Men with a family history of prostate cancer and African-American men are particularly susceptible to the disease, with a twofold to sevenfold increased risk. Assessing risk in these populations has been difficult.

17 Nov 2008

Expert calls on government to increase recommended daily vitamin D intake

Today, the Indoor Tanning Association (ITA) asked Texas Attorney General, Greg Abbott, why he is suing a local tanning salon owner for claiming that tanning provides vitamin D, when Vitamin D experts at the University of California Riverside are saying the same thing?

17 Nov 2008

Exercise can lower a woman's overall risk of cancer

Exercise is good for more than just your waistline. A recent study presented at the American Association for Cancer Research's Seventh Annual International Conference on Frontiers in Cancer Prevention Research suggests that regular physical activity can lower a woman's overall risk of cancer - but only if she gets a good night's sleep. Otherwise, lack of sleep can undermine exercise's cancer prevention benefits.

17 Nov 2008

Breast cancer common among women with family history but without BRCA1 or BRCA2 mutation

New data presented at the American Association for Cancer Research's Seventh Annual International Frontiers in Cancer Prevention Research meeting outlines new data, which assesses breast cancer risk among women with a strong family history of breast cancer, but without a BRCA1 or BRCA2 mutation.

17 Nov 2008